Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYMR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKymera Therapeutics reports Q1 2026 financial results
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
medium
Company announced first quarter 2026 financial results for period ended March 31, 2026. Detailed financials are in the press release furnished as an exhibit, not in the 8-K body itself.
Item 2.02 verify on EDGAR →
Summary
Kymera Therapeutics filed an 8-K to announce its first quarter 2026 financial results on April 30, 2026. This is a routine quarterly earnings disclosure required for public companies. The actual financial details—revenue, expenses, cash position, and any operational updates—are contained in the press release furnished as Exhibit 99.1, which is not included in the 8-K filing body itself.
For retail investors, this is a standard procedural filing with no immediate red flags. The materiality depends entirely on the content of the press release, which would show whether the company met, beat, or missed analyst expectations and provide updates on drug development programs. Investors should review the full press release and any accompanying earnings call transcript to assess the quarter's performance and management's forward guidance.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 30, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results on April 30, 2026. The actual financial details are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Kymera filed an 8-K to furnish a press release issued April 30, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press release issued by Kymera Therapeutics, Inc. on April 30, 2026, furnished herewith.
The company furnished a press release dated April 30, 2026 as Exhibit 99.1. The 8-K body does not disclose the content of the press release, so the nature and materiality of any announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify